Royal Bank of Canada reiterated their neutral rating on shares of Amgen (NASDAQ:AMGN) in a research report released on Monday. The brokerage currently has a $193.00 price objective on the medical research company’s stock.

Other equities analysts have also recently issued reports about the stock. TheStreet upgraded shares of Amgen from a c+ rating to a b- rating in a research report on Friday, May 25th. BidaskClub upgraded shares of Amgen from a buy rating to a strong-buy rating in a research report on Wednesday, July 11th. Piper Jaffray Companies upped their price target on shares of Amgen from $190.00 to $210.00 and gave the company an overweight rating in a research report on Thursday, July 26th. They noted that the move was a valuation call. Cann restated a buy rating and issued a $224.00 price target on shares of Amgen in a research report on Monday, July 30th. Finally, Oppenheimer reiterated a buy rating and set a $224.00 price objective on shares of Amgen in a research report on Tuesday, August 28th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $202.76.

Shares of NASDAQ AMGN opened at $202.93 on Monday. The company has a quick ratio of 3.12, a current ratio of 3.39 and a debt-to-equity ratio of 2.03. Amgen has a 52-week low of $163.31 and a 52-week high of $203.69. The company has a market capitalization of $129.13 billion, a price-to-earnings ratio of 14.82, a price-to-earnings-growth ratio of 1.94 and a beta of 1.39.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, July 26th. The medical research company reported $3.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.52 by $0.31. Amgen had a net margin of 10.19% and a return on equity of 43.18%. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $5.73 billion. During the same period in the prior year, the company posted $3.27 EPS. The company’s revenue was up 4.3% on a year-over-year basis. research analysts expect that Amgen will post 13.95 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 7th. Stockholders of record on Friday, August 17th were given a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.60%. The ex-dividend date was Thursday, August 16th. Amgen’s dividend payout ratio (DPR) is presently 41.97%.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Monday, July 16th. The shares were sold at an average price of $195.71, for a total value of $298,457.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.19% of the company’s stock.

A number of large investors have recently bought and sold shares of AMGN. Pzena Investment Management LLC grew its holdings in Amgen by 79,361.6% in the first quarter. Pzena Investment Management LLC now owns 1,341,311 shares of the medical research company’s stock worth $228,667,000 after purchasing an additional 1,339,623 shares during the period. Beutel Goodman & Co Ltd. acquired a new stake in Amgen in the second quarter worth $86,723,000. Natixis grew its holdings in Amgen by 2,612.1% in the second quarter. Natixis now owns 529,816 shares of the medical research company’s stock worth $97,799,000 after purchasing an additional 510,281 shares during the period. Old Mutual Global Investors UK Ltd. grew its holdings in Amgen by 775.0% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 532,015 shares of the medical research company’s stock worth $90,697,000 after purchasing an additional 471,216 shares during the period. Finally, Summit Trail Advisors LLC grew its holdings in Amgen by 16,458.8% in the first quarter. Summit Trail Advisors LLC now owns 433,510 shares of the medical research company’s stock worth $434,000 after purchasing an additional 430,892 shares during the period. Institutional investors and hedge funds own 77.20% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

See Also: Return on Equity (ROE)

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.